BiotechTube

Tirabrutinib

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Hodgkins Lymphoma

Conditions

Non Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia

Trial Timeline

Aug 17, 2012 → Jan 11, 2016

NCT ID
NCT01659255

About Tirabrutinib

Tirabrutinib is a phase 1 stage product being developed by Ono Pharmaceutical for Non Hodgkins Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01659255. Target conditions include Non Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia.

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07198087Phase 1Recruiting
NCT01659255Phase 1Completed

Competing Products

18 competing products in Non Hodgkins Lymphoma

See all competitors
ProductCompanyStageHype Score
Acalabrutinib + ACP-319AstraZenecaPhase 1/2
32
JBH492NovartisPhase 1
21
Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2CRochePhase 1/2
36
Obinutuzumab + Glofitamab + Gemcitabine + OxaliplatinRochePhase 2
42
Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + RituximabAmgenPhase 2
35
hLL2 (epratuzumab)Gilead SciencesPhase 1
21
Velcade + TemsirolimusPfizerPhase 2
35
Avelumab + Avelumab + Avelumab + Avelumab + Avelumab + AvelumabPfizerPhase 1
21
alemtuzumabSanofiPhase 1/2
24
Odronextamab + REGN5837Regeneron PharmaceuticalsPhase 1
36
Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + FludarabineBayerPhase 1/2
25
Rituximab + Fludarabine + CAMPTH-1HBayerPhase 2
32
Rituximab + CHOP + CVP + Ibritumomab TiuxetanBiogenPhase 2
32
Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y ZevalinBiogenPhase 2
32
tafasitamab + lenalidomide + parsaclisib + R-CHOPIncytePhase 1/2
33
UblituximabTG TherapeuticsPhase 1/2
29
Ublituximab + LenalidomideTG TherapeuticsPhase 1
18
XmAb13676XencorPhase 1
23